BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38048045)

  • 1. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
    Kurz SC; Zan E; Cordova C; Troxel AB; Barbaro M; Silverman JS; Snuderl M; Zagzag D; Kondziolka D; Golfinos JG; Chi AS; Sulman EP
    Clin Cancer Res; 2024 Feb; 30(4):680-686. PubMed ID: 38048045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas.
    Ivanidze J; Roytman M; Lin E; Magge RS; Pisapia DJ; Liechty B; Karakatsanis N; Ramakrishna R; Knisely J; Schwartz TH; Osborne JR; Pannullo SC
    J Neuroimaging; 2019 Sep; 29(5):650-656. PubMed ID: 31107591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.
    Rachinger W; Stoecklein VM; Terpolilli NA; Haug AR; Ertl L; Pöschl J; Schüller U; Schichor C; Thon N; Tonn JC
    J Nucl Med; 2015 Mar; 56(3):347-53. PubMed ID: 25635133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
    Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
    Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication.
    Dressen MS; Muthukrishnan A; Tragon TR; Lieberman FS; Mountz JM
    Clin Nucl Med; 2019 Jan; 44(1):e26-e27. PubMed ID: 30371576
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Kowalski ES; Khairnar R; Gryaznov AA; Kesari V; Koroulakis A; Raghavan P; Chen W; Woodworth G; Mishra M
    Radiat Oncol; 2021 Aug; 16(1):151. PubMed ID: 34399805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga-DOTA-peptide PET/CT for radiotherapy planning and evaluating treatment response in the management of meningiomas.
    Usmani S; Jain A; Hashmi SF; Mula-Hussain L; Riyami KA; Abubakar S; Shamim MS
    J Pak Med Assoc; 2023 Jun; 73(6):1340-1343. PubMed ID: 37427649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of
    Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
    J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of indigenous
    Sitani K; Parghane RV; Talole S; Basu S
    Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based
    Sundlöv A; Gleisner KS; Tennvall J; Ljungberg M; Warfvinge CF; Holgersson K; Hallqvist A; Bernhardt P; Svensson J
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3830-3840. PubMed ID: 35451612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications.
    Roytman M; Pisapia DJ; Liechty B; Lin E; Skafida M; Magge RS; Osborne JR; Pannullo SC; Knisely JPS; Ramakrishna R; Ivanidze J
    Clin Imaging; 2020 Oct; 66():18-22. PubMed ID: 32442855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
    Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
    Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
    Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Registry Study of
    Perlow HK; Nalin AP; Handley D; Gokun Y; Blakaj DM; Beyer SJ; Thomas EM; Raval RR; Boulter D; Kleefisch C; Bovi J; Chen WC; Braunstein SE; Raleigh DR; Knisely JPS; Ivanidze J; Palmer JD
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):979-985. PubMed ID: 37871886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?
    Sommerauer M; Burkhardt JK; Frontzek K; Rushing E; Buck A; Krayenbuehl N; Weller M; Schaefer N; Kuhn FP
    Neuro Oncol; 2016 Jul; 18(7):1021-7. PubMed ID: 26865086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of
    Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
    Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.